• LAST PRICE
    3.5500
  • TODAY'S CHANGE (%)
    Trending Down-0.0600 (-1.6620%)
  • Bid / Lots
    3.2500/ 3
  • Ask / Lots
    4.2500/ 1
  • Open / Previous Close
    3.4001 / 3.6100
  • Day Range
    Low 3.2501
    High 3.5500
  • 52 Week Range
    Low 2.4020
    High 11.7740
  • Volume
    9,177
    average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Mar 26, 2024

      Show headlines and story abstract
    • 7:30AM ET on Tuesday Mar 26, 2024 by Business Wire
      Companies Mentioned: VRPX

      Virpax(R) Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the twelve months ended December 31, 2023, and other recent developments.

    • 7:30AM ET on Tuesday Mar 26, 2024 by Dow Jones
      Companies Mentioned: VRPX
    • 7:30AM ET on Tuesday Mar 26, 2024 by Dow Jones
      Companies Mentioned: VRPX

      further development, including reporting results from additional pre-IND studies in advance of entering the clinic in 2024 and starting the USAISR's study mid year, and commercialization of Company drug candidates in current or future indications; the Company's ability to obtain additional grant funding, the uncertainties inherent in clinical testing; the Company's ability to manage and successfully complete clinical trials and the research and development efforts for multiple product candidates at varying stages of development; the timing, cost and uncertainty of obtaining regulatory approvals for the Company's product candidates; the Company's ability to protect its intellectual property; the loss of any executive officers or key personnel or consultants and the ability of such executives to make valuable contributions to the Company; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's product candidates; the Company's ability to continue to obtain capital to meet its short and long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to fulfill contractual obligations of its settlement, continue operations and commence and complete clinical trials that the Company plans to initiate; and other factors listed under "Risk Factors" in our annual report on Form 10-K and quarterly reports on Form 10-Q that the Company files with the U.S. Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Peers Headlines